Announcement • May 07
Xiamen Kingdomway Group Company (SZSE:002626) announces an Equity Buyback for CNY 400 million worth of its shares. Xiamen Kingdomway Group Company (SZSE:002626) announces a share repurchase program. Under the program, the company will repurchase not more than CNY 400 million worth of its A shares. The shares will be repurchased at a price of not more than CNY 25 per share. The repurchased shares will be used for company's equity incentive plan or subsequent employee stock ownership plan. The shares will be repurchased out of own funds. The plan will be valid for 12 months. Reported Earnings • Apr 21
Full year 2025 earnings released: EPS: CN¥0.56 (vs CN¥0.56 in FY 2024) Full year 2025 results: EPS: CN¥0.56 (in line with FY 2024). Revenue: CN¥3.37b (up 3.9% from FY 2024). Net income: CN¥339.9m (flat on FY 2024). Profit margin: 10% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Announcement • Apr 21
Xiamen Kingdomway Group Company, Annual General Meeting, May 13, 2026 Xiamen Kingdomway Group Company, Annual General Meeting, May 13, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China New Risk • Apr 13
New major risk - Revenue and earnings growth Earnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • Mar 31
Xiamen Kingdomway Group Company to Report Q1, 2026 Results on Apr 30, 2026 Xiamen Kingdomway Group Company announced that they will report Q1, 2026 results on Apr 30, 2026 Buy Or Sell Opportunity • Mar 25
Now 24% overvalued Over the last 90 days, the stock has fallen 13% to CN¥17.39. The fair value is estimated to be CN¥14.04, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.1% over the last 3 years. Earnings per share has grown by 18%. Revenue is forecast to grow by 46% in 2 years. Earnings are forecast to grow by 57% in the next 2 years. Valuation Update With 7 Day Price Move • Mar 23
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to CN¥16.35, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total loss to shareholders of 22% over the past three years. Announcement • Jan 07
Xiamen Kingdomway Group Company Receives New Dietary Ingredient (Ndi) Letter from the Food and Drug Administration Doctor's Best announced that its parent company, Xiamen Kingdomway Group, has received a New Dietary Ingredient (NDI) letter from the Food and Drug Administration (FDA) for its beta-Nicotinamide Mononucleotide (NMN) supplements. This FDA action permits the sale of NMN products by Kingdomway and marks a pivotal moment for the company and the broader supplement market. Key highlights of the FDA's decision include: Authorization for the sale of beta-Nicotinamide Mon onucleotide (NMN) in dietary supplements; Reversal of a prior regulatory interpretation that had restricted NMN's market presence; Enables Doctor's Best to relaunch its NMN product line and support consumer choice. While the FDA's decision confirms NMN's status under DSHEA, each company must still comply with the New Dietary Ingredient Notification (NDIN) process, applicable labeling, safety, and manufacturing requirements before marketing NMN products. Doctor's Best proudly adheres to the current federal guidelines governing the sale of NMN to consumers. Doctor's Best currently offers three NMN formulations, including NMN + Coq10 (150 mg), NMN+ (200 mg) and NMN Delayed Release (400 mg). Announcement • Dec 31
Xiamen Kingdomway Group Company to Report Fiscal Year 2025 Results on Apr 21, 2026 Xiamen Kingdomway Group Company announced that they will report fiscal year 2025 results on Apr 21, 2026 Reported Earnings • Oct 25
Third quarter 2025 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.18 (up from CN¥0.15 in 3Q 2024). Revenue: CN¥875.8m (up 6.9% from 3Q 2024). Net income: CN¥113.5m (up 25% from 3Q 2024). Profit margin: 13% (up from 11% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Announcement • Sep 30
Xiamen Kingdomway Group Company to Report Q3, 2025 Results on Oct 25, 2025 Xiamen Kingdomway Group Company announced that they will report Q3, 2025 results on Oct 25, 2025 Reported Earnings • Aug 28
Second quarter 2025 earnings released: EPS: CN¥0.21 (vs CN¥0.091 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.21 (up from CN¥0.091 in 2Q 2024). Revenue: CN¥901.2m (up 16% from 2Q 2024). Net income: CN¥125.6m (up 112% from 2Q 2024). Profit margin: 14% (up from 7.6% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 1% per year. Announcement • Jul 02
Xiamen Kingdomway Group Company to Report First Half, 2025 Results on Aug 26, 2025 Xiamen Kingdomway Group Company announced that they will report first half, 2025 results on Aug 26, 2025 Valuation Update With 7 Day Price Move • Jun 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥20.57, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total loss to shareholders of 9.7% over the past three years. Announcement • May 17
Xiamen Kingdomway Group Company Appoints Xu Xiaote as Non-Independent Director Xiamen Kingdomway Group Company held its 1st Extraordinary General Meeting of 2025 on 15 May 2025, during which the following proposal(s) was/were approved: Election of non-independent directors, cumulative voting system applicable: Xu Xiaote, non-independent director. Announcement • Apr 11
Xiamen Kingdomway Group Company Proposes Final Cash Dividend for the Year 2024 Xiamen Kingdomway Group Company proposed final cash dividend/10 shares (tax included) of CNY 4.00000000 for the year 2024. Announcement • Apr 10
Xiamen Kingdomway Group Company, Annual General Meeting, Apr 30, 2025 Xiamen Kingdomway Group Company, Annual General Meeting, Apr 30, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China Announcement • Mar 31
Xiamen Kingdomway Group Company to Report Q1, 2025 Results on Apr 29, 2025 Xiamen Kingdomway Group Company announced that they will report Q1, 2025 results on Apr 29, 2025 Announcement • Dec 31
Xiamen Kingdomway Group Company to Report Fiscal Year 2024 Results on Apr 10, 2025 Xiamen Kingdomway Group Company announced that they will report fiscal year 2024 results on Apr 10, 2025 Reported Earnings • Oct 27
Third quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.099 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.15 (up from CN¥0.099 in 3Q 2023). Revenue: CN¥819.3m (up 6.6% from 3Q 2023). Net income: CN¥90.7m (up 52% from 3Q 2023). Profit margin: 11% (up from 7.7% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 18% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥15.83, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 47% over the past three years. Announcement • Sep 30
Xiamen Kingdomway Group Company to Report Q3, 2024 Results on Oct 28, 2024 Xiamen Kingdomway Group Company announced that they will report Q3, 2024 results on Oct 28, 2024 Reported Earnings • Aug 29
Second quarter 2024 earnings released: EPS: CN¥0.091 (vs CN¥0.16 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.091 (down from CN¥0.16 in 2Q 2023). Revenue: CN¥780.2m (up 2.5% from 2Q 2023). Net income: CN¥59.3m (down 39% from 2Q 2023). Profit margin: 7.6% (down from 13% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings. Announcement • Jun 29
Xiamen Kingdomway Group Company to Report First Half, 2024 Results on Aug 29, 2024 Xiamen Kingdomway Group Company announced that they will report first half, 2024 results on Aug 29, 2024 Declared Dividend • May 31
Dividend of CN¥0.20 announced Dividend of CN¥0.20 is the same as last year. Ex-date: 6th June 2024 Payment date: 6th June 2024 Dividend yield will be 1.3%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (47% earnings payout ratio) and cash flows (66% cash payout ratio). The dividend has increased by an average of 2.5% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to decline by 48% to shift the payout ratio to a potentially unsustainable range, which is more than the 11% EPS decline seen over the last 5 years. Announcement • May 25
Xiamen Kingdomway Group Company Approves Cash Dividend for the Year 2023 Xiamen Kingdomway Group Company at its AGM held on May 22, 2024, approved cash dividend/10 shares (tax included) of CNY 2.00000000 for the year 2023. Announcement • May 02
Xiamen Kingdomway Group Company Proposes Final Cash Dividend for the Year 2023 Xiamen Kingdomway Group Company announced on 30 April 2024 the profit distribution proposal for the year 2023 as final cash dividend per ten shares (tax included) of CNY 2.00000000. Announcement • May 01
Xiamen Kingdomway Group Company, Annual General Meeting, May 22, 2024 Xiamen Kingdomway Group Company, Annual General Meeting, May 22, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Xiamen, Fujian China Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.12 (down from CN¥0.14 in 1Q 2023). Revenue: CN¥743.2m (down 6.0% from 1Q 2023). Net income: CN¥70.8m (down 19% from 1Q 2023). Profit margin: 9.5% (down from 11% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 28% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • Apr 08
Now 22% undervalued after recent price drop Over the last 90 days, the stock has fallen 7.3% to CN¥14.25. The fair value is estimated to be CN¥18.31, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has declined by 50%. Valuation Update With 7 Day Price Move • Apr 01
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥15.67, the stock trades at a trailing P/E ratio of 63x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 59% over the past three years. Announcement • Mar 30
Xiamen Kingdomway Group Company to Report Q1, 2024 Results on Apr 30, 2024 Xiamen Kingdomway Group Company announced that they will report Q1, 2024 results on Apr 30, 2024 Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to CN¥11.04, the stock trades at a trailing P/E ratio of 44.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in China. Total loss to shareholders of 63% over the past three years. Buy Or Sell Opportunity • Jan 22
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 22% to CN¥13.35. The fair value is estimated to be CN¥16.99, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.8% over the last 3 years. Earnings per share has declined by 50%. Announcement • Dec 30
Xiamen Kingdomway Group Company to Report Fiscal Year 2023 Results on Apr 10, 2024 Xiamen Kingdomway Group Company announced that they will report fiscal year 2023 results on Apr 10, 2024 New Risk • Dec 28
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 13% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (5.0% net profit margin). Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.099 (vs CN¥0.12 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.099 (down from CN¥0.12 in 3Q 2022). Revenue: CN¥769.0m (up 3.9% from 3Q 2022). Net income: CN¥59.5m (down 20% from 3Q 2022). Profit margin: 7.7% (down from 10.0% in 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.25 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.16 (down from CN¥0.25 in 2Q 2022). Revenue: CN¥761.2m (down 7.5% from 2Q 2022). Net income: CN¥97.1m (down 37% from 2Q 2022). Profit margin: 13% (down from 19% in 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Announcement • Aug 03
Xiamen Kingdomway Group Company announced a financing transaction Xiamen Kingdomway Group Company announced that it will raise a round of funding on August 1, 2023. The company will issue convertible corporate bonds in the transaction. The transaction has been approved in its 1st Extraordinary General Meeting of 2023 on August 1, 2023. Announcement • May 19
Xiamen Kingdomway Group Company Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 26 May 2023 Xiamen Kingdomway Group Company announced 2022 final profit distribution plan to be implemented (A shares) Cash dividend/10 shares (tax included): CNY 2.00000000. Record date: 25 May 2023, Ex-date: 26 May 2023 and Payment date: 26 May 2023. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY0.20000000(10 % x CNY 2.00000000) Net cash dividend/10 shares after tax: CNY1.80000000(CNY2.00000000- CNY0.20000000). Reported Earnings • Apr 24
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥0.43 (down from CN¥1.29 in FY 2021). Revenue: CN¥3.01b (down 17% from FY 2021). Net income: CN¥256.8m (down 67% from FY 2021). Profit margin: 8.5% (down from 22% in FY 2021). Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) also missed analyst estimates by 30%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Feb 14
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥24.87, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 16% over the past three years. Valuation Update With 7 Day Price Move • Dec 29
Investor sentiment improved over the past week After last week's 15% share price gain to CN¥21.18, the stock trades at a trailing P/E ratio of 27.4x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Total returns to shareholders of 14% over the past three years. Board Change • Nov 16
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. 2 highly experienced directors. Executive Deputy GM & Non-Independent Director Chen Jia Liang is the most experienced director on the board, commencing their role in 2001. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.26 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.12 (down from CN¥0.26 in 3Q 2021). Revenue: CN¥740.5m (down 20% from 3Q 2021). Net income: CN¥74.4m (down 53% from 3Q 2021). Profit margin: 10.0% (down from 17% in 3Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 17
Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.34 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.25 (down from CN¥0.34 in 2Q 2021). Revenue: CN¥823.0m (down 6.0% from 2Q 2021). Net income: CN¥154.0m (down 26% from 2Q 2021). Profit margin: 19% (down from 24% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 12% per year. Announcement • Jun 14
Xiamen Kingdomway Group Company Announces Cash Dividend for A Shares for the Year 2021, Payable on 17 June 2022 Xiamen Kingdomway Group Company announced cash dividend/10 shares (tax included) of CNY 6.00000000 for A shares for the year 2021. Record date is 16 June 2022. Ex-date is 17 June 2022. Payment date is 17 June 2022. Board Change • Jun 02
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. 2 highly experienced directors. Executive Deputy GM & Non-Independent Director Chen Jia Liang is the most experienced director on the board, commencing their role in 2001. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • May 19
Xiamen Kingdomway Group Company Approves Board Appointments Xiamen Kingdomway Group Company announced that at its Extraordinary General Meeting of 2022 held on May 17, 2022, elected Wu Yi, Gu Weihua as non-independent directors, Wang Dahong, Wang Xiaojian, Zong Geng as independent directors and Jiao Jie, Lin Shuishan as shareholder supervisors. Announcement • May 12
Xiamen Kingdomway Group Company Approves 2021 Profit Distribution Plan At the Annual General Meeting Held on May 6, 2022 Xiamen Kingdomway Group Company approved 2021 profit distribution plan at the Annual General Meeting held on May 6, 2022. The company approved Cash dividend/10 shares (tax included)of CNY 6.00000000. Reported Earnings • Apr 29
First quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.49 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.20 (down from CN¥0.49 in 1Q 2021). Revenue: CN¥741.4m (down 18% from 1Q 2021). Net income: CN¥120.3m (down 60% from 1Q 2021). Profit margin: 16% (down from 33% in 1Q 2021). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 12
Full year 2021 earnings released: EPS: CN¥1.29 (vs CN¥1.57 in FY 2020) Full year 2021 results: EPS: CN¥1.29 (down from CN¥1.57 in FY 2020). Revenue: CN¥3.62b (up 3.2% from FY 2020). Net income: CN¥788.9m (down 18% from FY 2020). Profit margin: 22% (down from 27% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 23% per year. Valuation Update With 7 Day Price Move • Mar 21
Investor sentiment improved over the past week After last week's 20% share price gain to CN¥33.91, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total returns to shareholders of 159% over the past three years. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment improved over the past week After last week's 24% share price gain to CN¥33.06, the stock trades at a trailing P/E ratio of 24.3x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total returns to shareholders of 162% over the past three years. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.49 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥927.6m (down 3.4% from 3Q 2020). Net income: CN¥158.6m (down 47% from 3Q 2020). Profit margin: 17% (down from 31% in 3Q 2020). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 35% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.45 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: CN¥875.6m (up 8.4% from 2Q 2020). Net income: CN¥206.6m (down 26% from 2Q 2020). Profit margin: 24% (down from 34% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 31% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 02
First quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.36 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥901.3m (up 13% from 1Q 2020). Net income: CN¥300.2m (up 38% from 1Q 2020). Profit margin: 33% (up from 27% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 30% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥1.57 (vs CN¥0.73 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥3.50b (up 9.8% from FY 2019). Net income: CN¥959.2m (up 113% from FY 2019). Profit margin: 27% (up from 14% in FY 2019). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 32% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Feb 25
Xiamen Kingdomway Group Company to Report Fiscal Year 2020 Results on Mar 31, 2021 Xiamen Kingdomway Group Company announced that they will report fiscal year 2020 results on Mar 31, 2021 Is New 90 Day High Low • Jan 20
New 90-day low: CN¥30.24 The company is down 25% from its price of CN¥40.17 on 22 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Is New 90 Day High Low • Nov 25
New 90-day low: CN¥33.62 The company is down 20% from its price of CN¥42.13 on 27 August 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 10.0% over the same period. Reported Earnings • Nov 01
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥716.9m, up 27% from the prior year. Total revenue was CN¥3.46b over the last 12 months, up 12% from the prior year. Valuation Update With 7 Day Price Move • Oct 14
Market bids up stock over the past week After last week's 16% share price gain to CN¥40.77, the stock is trading at a trailing P/E ratio of 43.2x, up from the previous P/E ratio of 37.3x. This compares to an average P/E of 40x in the Pharmaceuticals industry in China. Total returns to shareholders over the past three years are 202%. Announcement • Jul 25
Xiamen Kingdomway Group Company to Report First Half, 2020 Results on Aug 21, 2020 Xiamen Kingdomway Group Company announced that they will report first half, 2020 results on Aug 21, 2020